TY - JOUR
T1 - Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings
AU - Tuboi, Suely Hiromi
AU - Pacheco, Antonio Guilherme
AU - Harrison, Lee H.
AU - Stone, Roslyn A.
AU - May, Margaret
AU - Brinkhof, Martin W.G.
AU - Dabis, François
AU - Egger, Matthias
AU - Nash, Denis
AU - Bangsberg, David
AU - Braitstein, Paula
AU - Yiannoutsos, Constantin T.
AU - Wood, Robin
AU - Sprinz, Eduardo
AU - Schechter, Mauro
PY - 2010/1
Y1 - 2010/1
N2 - OBJECTIVES: We assessed mortality associated with immunologic and virologic patterns of response at 6 months of highly active antiretroviral therapy (HAART) in HIV-infected individuals from resource-limited countries in Africa and South America. METHODS: Patients who initiated HAART between 1996 and 2007, aged 16 years or older, and had at least 1 measurement (HIV-1 RNA plasma viral load or CD4 cell count) at 6 months of therapy (3-9 month window) were included. Therapy response was categorized as complete, discordant (virologic only or immunologic only), and absent. Associations between 6-month response to therapy and all-cause mortality were assessed by Cox proportional hazards regression. Robust standard errors were calculated to account for intrasite correlation. RESULTS: A total of 7160 patients, corresponding to 15,107 person-years, were analyzed. In multivariable analysis adjusted for age at HAART initiation, baseline clinical stage and CD4 cell count, year of HAART initiation, clinic, occurrence of an AIDS-defining condition within the first 6 months of treatment, and discordant and absent responses were associated with increased risk of death. CONCLUSIONS: Similar to reports from high-income countries, discordant immunologic and virologic responses were associated with intermediate risk of death compared with complete and no response in this large cohort of HIV-1 patients from resource-limited countries. Our results support a recommendation for wider availability of plasma viral load testing to monitor antiretroviral therapy in these settings.
AB - OBJECTIVES: We assessed mortality associated with immunologic and virologic patterns of response at 6 months of highly active antiretroviral therapy (HAART) in HIV-infected individuals from resource-limited countries in Africa and South America. METHODS: Patients who initiated HAART between 1996 and 2007, aged 16 years or older, and had at least 1 measurement (HIV-1 RNA plasma viral load or CD4 cell count) at 6 months of therapy (3-9 month window) were included. Therapy response was categorized as complete, discordant (virologic only or immunologic only), and absent. Associations between 6-month response to therapy and all-cause mortality were assessed by Cox proportional hazards regression. Robust standard errors were calculated to account for intrasite correlation. RESULTS: A total of 7160 patients, corresponding to 15,107 person-years, were analyzed. In multivariable analysis adjusted for age at HAART initiation, baseline clinical stage and CD4 cell count, year of HAART initiation, clinic, occurrence of an AIDS-defining condition within the first 6 months of treatment, and discordant and absent responses were associated with increased risk of death. CONCLUSIONS: Similar to reports from high-income countries, discordant immunologic and virologic responses were associated with intermediate risk of death compared with complete and no response in this large cohort of HIV-1 patients from resource-limited countries. Our results support a recommendation for wider availability of plasma viral load testing to monitor antiretroviral therapy in these settings.
KW - Antiretroviral therapy
KW - CD4 lymphocyte count
KW - Cohort
KW - Highly active
KW - Low-income population
KW - Mortality
KW - Treatment outcome
KW - Viral load
UR - http://www.scopus.com/inward/record.url?scp=74049160029&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74049160029&partnerID=8YFLogxK
U2 - 10.1097/QAI.0b013e3181c22d19
DO - 10.1097/QAI.0b013e3181c22d19
M3 - Article
C2 - 20035163
AN - SCOPUS:74049160029
SN - 1525-4135
VL - 53
SP - 70
EP - 77
JO - Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
JF - Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
IS - 1
ER -